Cheryl Bunk
Medical · Shickshinny, PANPI 1285730663
Payments from drug & device makers
Across 256 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$904
- Novo Nordisk$665
- Amgen$542
- Boehringer Ingelheim$359
- Johnson & Johnson$346
- AstraZeneca$286
- plus $1K from 20 others
What the payments were for
- Food & beverage$4,382100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 61 | $904 |
| Novo Nordisk | 37 | $665 |
| Amgen | 32 | $542 |
| Boehringer Ingelheim | 19 | $359 |
| Johnson & Johnson | 21 | $346 |
| AstraZeneca | 17 | $286 |
| GSK | 14 | $230 |
| Bayer | 9 | $160 |
| Exact Sciences | 7 | $152 |
| Pfizer | 7 | $141 |
| AbbVie | 3 | $74 |
| Sanofi-aventis U.S. LLC | 4 | $67 |
| Verona Pharma, Inc. | 3 | $61 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $55 |
| Phathom Pharmaceuticals, Inc. | 3 | $53 |
| Esperion Therapeutics, Inc. | 2 | $44 |
| Kyowa Kirin, Inc. | 2 | $44 |
| Dexcom, Inc. | 2 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| Amarin Pharma, Inc. | 2 | $25 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Novartis | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Abbott | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
How this compares
$4,382 in reported general payments places this provider in the 85th percentile of 2,594 medical providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 34 | $40,993 |
| TrulicityDulaglutide | 15 | $21,431 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $11,464 |
| Novolog FlexpenInsulin Aspart | 30 | $10,533 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $2,960 |
| Rosuvastatin Calcium | 68 | $1,422 |
| Levothyroxine Sodium | 88 | $1,368 |
| Lisinopril | 94 | $1,152 |
| Atorvastatin Calcium | 104 | $1,034 |
| Gabapentin | 43 | $1,024 |
| Fluticasone Propionate | 47 | $925 |
| Omeprazole | 85 | $857 |
| Amlodipine Besylate | 66 | $798 |
| Potassium Chloride | 35 | $738 |
| Simvastatin | 69 | $699 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $359 | $40,99334 claims |
| Lilly USA, LLCTrulicity | $904 | $21,43115 claims |
| GSKTrelegy Ellipta | $230 | $11,46416 claims |
| AbbVieArmour Thyroid | $74 | $40412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Shickshinny
- Jacqueline KernaghanSpringfield$427K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Shelley SassamanTamaqua$90K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
- Scott CoxWynnewood$66K
- Sarah SmithPhiladelphia$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.